The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 26, 2025
Filed:
Jan. 14, 2022
Applicant:
Japan Tobacco Inc., Tokyo, JP;
Inventors:
Hironobu Nagamori, Osaka, JP;
Ikuo Mitani, Osaka, JP;
Masaki Yamashita, Osaka, JP;
Takahiro Hotta, Osaka, JP;
Yuichi Nakagawa, Osaka, JP;
Masatoshi Ueda, Osaka, JP;
Assignee:
Japan Tobacco Inc., Tokyo, JP;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 251/22 (2006.01); A61K 31/53 (2006.01); A61K 45/06 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01); A61P 17/00 (2006.01); A61P 19/00 (2006.01); A61P 19/02 (2006.01); A61P 25/00 (2006.01); A61P 25/04 (2006.01); A61P 25/28 (2006.01); A61P 27/00 (2006.01); A61P 27/02 (2006.01); A61P 27/06 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 43/00 (2006.01); C07D 401/04 (2006.01); C07D 401/10 (2006.01); C07D 401/12 (2006.01); C07D 403/10 (2006.01); C07D 405/12 (2006.01); C07D 471/10 (2006.01);
U.S. Cl.
CPC ...
C07D 251/22 (2013.01); A61K 31/53 (2013.01); A61K 45/06 (2013.01); A61P 27/06 (2018.01); C07D 401/04 (2013.01); C07D 401/10 (2013.01); C07D 401/12 (2013.01); C07D 403/10 (2013.01); C07D 405/12 (2013.01); C07D 471/10 (2013.01);
Abstract
Provided is a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and cancer including colorectal cancer. A compound represented by the formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the SPECIFICATION.